Skip to content

Efficacy of different drugs in the non-invasive treatment of clearing high-risk HPV persistent infection

Efficacy of different drugs in the non-invasive treatment of clearing high-risk HPV persistent infection

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043973
Enrollment
Unknown
Registered
2021-03-06
Start date
2021-03-05
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk HPV persistent infection

Interventions

Sponsors

Anhui Province Maternity and Child Healthcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Women between 18 and 70 years old with sexual life, but non-pregnant or lactating; (2) Persistent hrHPV infection for more than twelve months; (3) For each individual patient, only either HPV genotyping test or HPV E6/E7 mRNA assay was used for the examination of hrHPV infection during whole observation from the screening of enrollment to the end of follow-up; (4) Without a high level of cervical lesions [no more than grade one cervical intraepithelial neoplasia (CIN I) according to the examination of colposcopy and biopsy]; (5) No previous anti-HPV intervention.

Exclusion criteria

Exclusion criteria: (1) With a history of allergy, smoking, oral contraceptive and HPV vaccination; (2) With severe heart, lung, liver and kidney dysfunction; (3) Women who cant complete the designed drug administration due to menstrual disorder.

Design outcomes

Primary

MeasureTime frame
HPV E6E7 mRNA;HPV-DNA genotyping test;

Countries

China

Contacts

Public ContactShuguang Zhou

Anhui Province Maternity and Child Healthcare Hospital

zhoushuguang@ahmu.edu.cn+86 13955117688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026